Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge

Addy, 2015, Improvements in symptomatic treatment strategies for cystic fibrosis: delivering CF care in the 21st century, Expert Opin Orph Drugs, 4, 1 Stoltz, 2015, Origins of cystic fibrosis lung disease, N Engl J Med, 372, 351, 10.1056/NEJMra1300109 Sly, 2013, Risk factors for bronchiectasis in children with cystic fibrosis, N Engl J Med, 368, 1963, 10.1056/NEJMoa1301725 Cohen-Cymberknoh, 2013, Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications, Thorax, 68, 1157, 10.1136/thoraxjnl-2013-203204 Rosen, 2018, Infection is not required for muco-inflammatory Lung Disease in CFTR-Knockout Ferrets, Am J Respir Crit Care Med, 197, 1308, 10.1164/rccm.201708-1616OC Schultz A; Stick, 2015, Early pulmonary inflammation and lung damage in children with Cystic Fibrosis, Respirol, 20, 569, 10.1111/resp.12521 Chen, 2010, Sterile Inflammation: Sensing and Reacting to Damage, Nat Rev Immunol, 10, 826, 10.1038/nri2873 Roesch, 2018, Inflammation in Cystic Fibrosis: An Update, Pediatr Pulmonol, 53, S30, 10.1002/ppul.24129 Houston C, Taggart CT and Downey DG. The role of inflammation in cystic fibrosis pulmonary exacerbations. Expert Rev Respir MedJun 2020. doi.org/10.1080/17476348.2020.1778469 Harris, 2020, Changes in airway microbiome and inflammation with ivacaftor treatment in patients with Cystic Fibrosis and the G551D mutation, Ann Am Thorac Soc, 17, 212, 10.1513/AnnalsATS.201907-493OC Dhooghe, 2014, Lung inflammation in cystic fibrosis: Pathogenesis and novel therapies, Clin Biochem, 47, 539, 10.1016/j.clinbiochem.2013.12.020 Fayon, 2014, Clinimetric properties of bronchoalveolar lavage inflammatory markers in cystic fibrosis, ERJ, 43, 610, 10.1183/09031936.00017713 Ramsey, 2015, Biomarkers in Paediatric Cystic Fibrosis Lung Disease, Paediatr Respir Rev, 16, 213 Ronchetti, 2018, The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial, Lancet Respir Med, 6, 461, 10.1016/S2213-2600(18)30171-1 Henig, 2001, Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis, Thorax, 56, 306, 10.1136/thorax.56.4.306 De Boeck, 2000, Sputum Induction in Young Cystic Fibrosis Patients, ERJ, 16, 91, 10.1034/j.1399-3003.2000.16a16.x FDA-NIH Biomarker Working group. BEST (Biomarkers, Endpoints, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethseda (MD): NIH (US) 2016 [last updated Jan 25; 2021]. Muhlebach, 2016, Biomarkers for cystic fibrosis drug development, J Cyst Fibros, 15, 714, 10.1016/j.jcf.2016.10.009 Taggart, 2017, Protean proteases: at the cutting edge of lung diseases, ERJ, 49, 10.1183/13993003.01200-2015 Kent, 2014, Lung clearance index: evidence for use in clinical trials in cystic fibrosis, J Cyst Fibros, 13, 123, 10.1016/j.jcf.2013.09.005 Eickmeier, 2013, Transforming Growth Factor B1 Genotypes in Relation to TDFB1, Interleukin-8 and Tumor Necrosis Factor Alpha in Induced Sputum and Blood in Cystic Fibrosis, Med of Inflamm, 10.1155/2013/913135 Xiao, 2005, Urokinase Plasminogen Activation System Components, and Cytokines Discriminate Cystic Fibrosis, COPD, and Asthma Inflammation, Chest, 128, 2316, 10.1378/chest.128.4.2316 Sagel, 2001, Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction, Am J Respir Crit Care Med, 164, 1425, 10.1164/ajrccm.164.8.2104075 Osika, 1999, Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease, ERJ, 14, 339, 10.1183/09031936.99.14233999 Richman-Eisenstat, 1993, Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway disease, Am J Physiol, 264, 413 Schuster, 1995, Cytokines in neutrophil-dominated airway inflammation in patients with cystic fibrosis, Eur Arch Otorhinolaryngol, 252, S59, 10.1007/BF02484436 Müller, 2015, Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic Therapy, Med Inflamm, 10.1155/2015/626530 Gaggar, 2007, Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients, Am J Physiol Lung Cell Mol Physiol, 293, L96, 10.1152/ajplung.00492.2006 Koller, 1997, Cytokine concentrations in sputum from patients with cystic fibrosis and their relation to eosinophil activity, Am J Resp Crit Care Med, 155, 1050, 10.1164/ajrccm.155.3.9116985 Smith, 2014, Elevated metal concentrations in the CF airway correlate with cellular injury and disease severity, J Cyst Fibros, 13, 289, 10.1016/j.jcf.2013.12.001 Reid, 2004, Airway iron and iron-regulatory cytokines in cystic fibrosis, ERJ, 24, 286, 10.1183/09031936.04.00104803 Pauwels, 2012, Bile acids in sputum and increased airway inflammation in patients with cystic fibrosis, Chest, 141, 1568, 10.1378/chest.11-1573 Gray, 2010, Sputum trace metals are biomarkers of inflammatory and suppurative lung disease, Chest, 137, 635, 10.1378/chest.09-1047 Mayer-Hamblett, 2007, Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis, Proc Amer Thorac Soc, 4, 370, 10.1513/pats.200703-040BR Sagel, 2002, Induced Sputum Inflammatory Measures Correlate with Lung Function in Children with Cystic Fibrosis, J Pedatrics, 141, 811, 10.1067/mpd.2002.129847 Sagel, 2012, Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis, Am J Respir Crit Care Med, 186, 857, 10.1164/rccm.201203-0507OC Henry, 1998, Airway Inflammation After Treatment with Aerolsolized Deoxyribonuclease in Cystic Fibrosis, Ped Pulmonol, 26, 97, 10.1002/(SICI)1099-0496(199808)26:2<97::AID-PPUL4>3.0.CO;2-E Horsley, 2013, Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation, Thorax, 68, 532, 10.1136/thoraxjnl-2012-202538 Ratjen, 2016, Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia, ERJ, 47, 829, 10.1183/13993003.01390-2015 Kim, 2006, Pulmonary function is negatively correlated with sputum inflammatory markers and cough clearability in subjects with cystic fibrosis but not those with chronic bronchitis, Chest, 129, 1148, 10.1378/chest.129.5.1148 Jain, 2020, Evaluation of airway and circulating inflammatory biomarkers for cystic fibrosis drug development, J Cyst Fibros Karpati, 2000, TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment, Scand J Infect Dis, 32, 75, 10.1080/00365540050164263 Wolter, 1999, Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis, Clin Diagn Lab Immunol, 6, 260, 10.1128/CDLI.6.2.260-265.1999 Rochat, 1996, Aerosolized rhDNase in cystic fibrosis: effect on leucocyte proteases in sputum, ERJ, 9, 2200, 10.1183/09031936.96.09112200 O'Connor, 1993, Alpha 1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis, Am Rev Respir Dis, 6, 1665, 10.1164/ajrccm/148.6_Pt_1.1665 Mussaffi, 2008, Induced sputum in the very young: a new key to infection and inflammation, Chest, 133, 176, 10.1378/chest.07-2259 Zemanick, 2015, Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods, Ann Am Thorac Soc, 12, 221, 10.1513/AnnalsATS.201407-310OC Moffitt, 2014, Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis, J Cyst Fibros, 13, 63, 10.1016/j.jcf.2013.06.002 Liou, 2012, Sputum Biomarkers and the Prediction of Clinical Outcomes in Patients with Cystic Fibrosis, PLoS One, 7, e42748, 10.1371/journal.pone.0042748 Rowe, 2008, Potential of High-Mobility Group Box 1 in Cystic Fibrosis Airway Disease, Am J Respir Crit Care Med, 178, 822, 10.1164/rccm.200712-1894OC Martin, 2010, Association of airway cathepsin B and S with inflammation in cystic fibrosis, Pediatr Pulmonol, 45, 860, 10.1002/ppul.21274 Laguna, 2015, Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis, J Cystic Fibr, 14, 334, 10.1016/j.jcf.2014.10.002 Griese, 2007, Alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients, Eur Respir J, 29, 240, 10.1183/09031936.00047306 Salva, 1996, TNF-α, IL-8, Soluble ICAM-1, and neutrophils in Sputum of Cystic Fibrosis Patients, Ped Pulmonol, 21, 11, 10.1002/(SICI)1099-0496(199601)21:1<11::AID-PPUL2>3.0.CO;2-T Liou, 2019, Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis, BMC Med Res Methodol, 19, 88, 10.1186/s12874-019-0705-0 Fischer, 2014, Non-invasive assessment of upper and lower airway infection and inflammation in CF patients, Pediatr Pulmonol, 49, 1065, 10.1002/ppul.22982 Colombo, 2011, Analysis of Inflammatory and Immune Response Biomarkers in Sputum and Exhaled Breath Condensate by a Multi-Parametric Biochip Array in Cystic Fibrosis, International J Immunopathol and Pharmacol, 24, 423, 10.1177/039463201102400215 Kronborg, 1993, Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs, Pediatr Pulmonol, 15, 292, 10.1002/ppul.1950150506 Laguna, 2009, Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis, Chest, 136, 1561, 10.1378/chest.09-0217 Chiron, 2008, Lipoxin A4 and interleukin-8levels in cystic fibrosis sputum after antibiotherapy, J Cyst Fibros, 7, 463, 10.1016/j.jcf.2008.04.002 Colombo, 2005, Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy, Pediatr Pulmonol, 40, 15, 10.1002/ppul.20237 Pukhalsky, 2004, Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease, Mediators Inflamm, 13, 111, 10.1080/09629350410001688495 Ordoñez, 2003, Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis, Am J Respir Crit Care Med, 168, 1471, 10.1164/rccm.200306-731OC Waters, 2015, Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients, J Cyst Fibros, 14, 755, 10.1016/j.jcf.2015.01.007 Pukhalsky, 1999, Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection, Mediators Inflamm, 8, 159, 10.1080/09629359990496 Saiman, 2003, Azithromycin in Patients with Cystic fibrosis Chronically Infected with Pseudomonas Aeruginosa: A randomized controlled trial, JAMA, 290, 1749, 10.1001/jama.290.13.1749 Husson, 2005, Effect of intermittent inhaled tobramycin on sputum cytokine profiles in cystic fibrosis, J Antimicrob Chemother, 56, 247, 10.1093/jac/dki179 Koller, 1994, Eosinophilic activation in cystic fibrosis, Thorax, 49, 496, 10.1136/thx.49.5.496 Balfour-Lynn, 1997, Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis, Arch Dis Child, 77, 124, 10.1136/adc.77.2.124 Martin, 2006, Recombinant AAT CF Study Team. Safety and efficacy of recombinant alpha (1)-antitrypsin therapy in cystic fibrosis, Pediatr Pulmonol, 41, 177, 10.1002/ppul.20345 Chmiel, 2020, Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis, J Cyst Fibrosis, 1569 Elborn, 2012, Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis, ERJ, 40, 969, 10.1183/09031936.00194611 Keown, 2020, Airway Inflammation and Host Responses in the Era of CFTR Modulators, Int J Mol Sci, 21, 6379, 10.3390/ijms21176379 Houston, 2020, The role of inflammation in cystic fibrosis pulmonary exacerbations, Expert Rev Respir Med, 14, 889, 10.1080/17476348.2020.1778469 Moss, 2004, Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial, Chest, 125, 509, 10.1378/chest.125.2.509 Hisert, 2017, Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections, Am J Resp Crit Care Med, 195, 1617, 10.1164/rccm.201609-1954OC Ledson, 2001, Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients, ERJ, 17, 36, 10.1183/09031936.01.17100360 Shah, 1996, The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis, ERJ, 9, 531, 10.1183/09031936.96.09030531 Costello, 1996, Effects of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis, Thorax, 51, 619, 10.1136/thx.51.6.619 Tirouvanziam, 2006, High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis, PNAS, 103, 4628, 10.1073/pnas.0511304103 Suri, 2003, Safety and Use of Sputum Induction in Children with Cystic Fibrosis, Ped Pulmonol, 35, 309, 10.1002/ppul.10226 Woolhouse, 2002, Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis, Thorax, 57, 667, 10.1136/thorax.57.8.667 Louis, 1999, The effect of processing on inflammatory markers in induced sputum, ERJ, 13, 660, 10.1183/09031936.99.13366099 Efthimiadis, 1997, Induced sputum cell and fluid-phase indices of inflammation: comparison of treatment with dithiothretiol vs phosphate-buffered saline, ERJ, 10, 1336, 10.1183/09031936.97.10061336 McElvaney, 2019, A specialized method of sputum collection and processing for therapeutic interventions in cystic fibrosis, J Cyst Fibros, 18, 203, 10.1016/j.jcf.2018.06.001 Giddings, 2017, Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers. Ped Pulmonol, Ped Pulmonol, 52, S21, 10.1002/ppul.23768 Nicholas, 2009, Induced sputum: a window to lung pathology, Biochem Soc Trans, 37, 868, 10.1042/BST0370868 NE, 2001, Induced sputum derives from the central airways: confirmation using a radio-labelled aerosol bolus delivery technique, AJRCCM, 164, 1964 Radhakrishnan, 2007, Realities of expectorated sputum collection in the pediatric cystic fibrosis clinic, Arch Pediatr Adolesc Med, 161, 603, 10.1001/archpedi.161.6.603 Dean, 1993, Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis, Pediatr Res, 159, 10.1203/00006450-199308000-00010 Eickmeier, 2010, Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function, Cytokine, 50, 152, 10.1016/j.cyto.2010.02.004 Hector, 2011, The Chitinase-Like Protein YKL-40 Modulates Cystic Fibrosis, PLoS One, 6, e24399, 10.1371/journal.pone.0024399 Hauber, 2008, Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients, Int J Med Sci, 5, 371, 10.7150/ijms.5.371 Weber, 2001, Activation of NF-κB in airway epithelial cells is dependent on CFTR trafficking and Cl − channel function, Am J Physiol Cell Mol Physiol, 281, L71, 10.1152/ajplung.2001.281.1.L71 Chmiel, 2015, Assessment of Induced Sputum in Cystic Fibrosis Study Group. Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis, J Cystic Fibros, 14, 720, 10.1016/j.jcf.2015.03.007 Hector, 2014, The chemokine CCL18 characterises Pseudomonas infections in cystic fibrosis lung disease, ERJ, 44, 1608, 10.1183/09031936.00070014 Gershman, 1999, Fractional analysis of sequential induced sputum samples during sputum induction: evidence that different lung compartments are sampled at different time points, J Allergy Clin Immunol, 104, 322, 10.1016/S0091-6749(99)70374-X Holz, 1998, Changes in sputum composition during sputum induction in healthy and asthmatic subjects, Clin Experim Allergy, 28, 284, 10.1046/j.1365-2222.1998.00243.x Holz, 1998, Changes in sputum composition between two inductions performed on consecutive days, Thorax, 53, 83, 10.1136/thx.53.2.83 European Cystic Fibrosis Society-Clinical Trial Network: 3.1/003 Spirometry for 6 years and older: Standard Operating Procedure Version 2.0 25th March 2020. Available upon request from [email protected] European Cystic Fibrosis Society-Clinical Trial Network: 2.5/001 Inflammatory Mediators in Cystic Fibrosis Patients: Bronchoalveolar Lavage Through a Flexible Bronchoscope: Standard Operating Procedure. 4th March 2015. Available upon request from [email protected] Kim, 2001, Sputum processing for evaluation of inflammatory mediators, Pediatr Pulmonol, 32, 152, 10.1002/ppul.1101 Hair, 2017, Complement effectors, C5a and C3a, in cystic fibrosis lung fluid correlate with disease severity, PLoS One, 12, 10.1371/journal.pone.0173257 Taylor-Cousar, 2015, Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease, J Cyst Fibros, 14, 228, 10.1016/j.jcf.2014.10.006 Moss, 2013, Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis, J Cyst Fibros, 12, 241, 10.1016/j.jcf.2012.08.016 Chirico, 2015, Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGBI) between inflammation and infection, Clin Microbiol Infect, 21, 368e1, 10.1016/j.cmi.2014.11.004 Leonardi, 2016, YKL-40 as marker of severe lung disease in cystic fibrosis patients, J Cyst Fibros, 15, 583, 10.1016/j.jcf.2015.12.020 Devereux, 2014, An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis, J Cyst Fibros, 13, 557, 10.1016/j.jcf.2014.01.010 Gaggar, 2016, Inhaled alpha1-protinease inhibitor therapy in patients with cystic fibrosis, J Cyst Fibrosis, 15, 227, 10.1016/j.jcf.2015.07.009 Rowe, 2014, Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis, Am J Respir Crit Care Med, 190, 175, 10.1164/rccm.201404-0703OC ECFS-CTN: Blau H and Mussaffi H. Sputum Induction SOP 2.4/001 2014 Suri, 2002, Effects of recombinant human DNase and hypertonic saline on airway inflammation in chikdren with cystic fibrosis, Am J Respir Crit Care Med, 166, 352, 10.1164/rccm.2110015 Reeves, 2011, Nebulized Hypertonic Saline Decreases IL-8 in Sputum of Patients with Cystic Fibrosis, Am J Respir Crit Care Med, 10.1164/rccm.201101-0072OC Hamblett, 2007, Association between pulmonary function and sputum biomarkers in cystic fibrosis, Am J Respir Crit Care Med, 175, 822, 10.1164/rccm.200609-1354OC Chalmers, 2020, Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis, NEJM, 383, 2127, 10.1056/NEJMoa2021713 U.S. Food and Drug Administration. Draft Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. December 2012. Accessed 7 March 2016. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf Accurso, 2014, Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data, J Cyst Fibros, 13, 139, 10.1016/j.jcf.2013.09.007 Xu, 2017, Doxycycline improves clinical outcomes during cystic fibrosis exacerbations, ERJ, 49, 10.1183/13993003.01102-2016 Shoki, 2013, Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations, Chest, 144, 1659, 10.1378/chest.13-0693 Konstan, 2008, Ibuprofen therapy for cystic fibrosis lung disease: Revisited, Curr Opin Pulm Med, 14, 567, 10.1097/MCP.0b013e32831311e8 Anil, 2010, Induced sputum nitrites correlate with FEV1 in children with cystic fibrosis, Acta Paed, 99, 711, 10.1111/j.1651-2227.2010.01682.x Greally, 1993, Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis, Arch Dis Child, 68, 389, 10.1136/adc.68.3.389 Vasu, 2011, Evaluation of Thiol-based Antioxidant Therapeutics in Cystic Fibrosis Sputum: Focus on Myeloperoxidase, Free Radic Res, 45, 165, 10.3109/10715762.2010.521154 Papas, 2008, A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis, J Cyst Fibros, 7, 60, 10.1016/j.jcf.2007.05.001 Conrad, 2015, Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial, J Cyst Fibros, 14, 219, 10.1016/j.jcf.2014.08.008 Dauletbaev, 2009, A Phase II Study on Safety and Efficacy of High-Dose N-Acetylcysteine in Patients with Cystic Fibrosis, Eur J Med Res, 14, 352, 10.1186/2047-783X-14-8-352 Downey, 2007, The Relationship of Clinical and Inflammatory Markers to Outcome in Stable Patients with Cystic Fibrosis, Ped Pulmonol, 42, 216, 10.1002/ppul.20553 Jones, 2003, Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa, ERJ, 22, 503, 10.1183/09031936.03.00004503 McGarvey, 2002, Cytokine concentrations and neutrophil elastase activity in bronchoalveolar lavage and induced sputum from patients with cystic fibrosis, mild asthma and healthy volunteers, J Cyst Fibros, 1, 269, 10.1016/S1569-1993(02)00098-X Ordoñez, 2001, Effects of Clarithromycin on Airway Obstruction and Inflammatory Markers in Induced Sputum in Cystic Fibrosis: A Pilot Study, Ped Pulmonol, 32, 29, 10.1002/ppul.1085 Smountas, 2004, Induced sputum in cystic fibrosis: within-week reproducibility of inflammatory markers, Clin Biochem, 37, 1031, 10.1016/j.clinbiochem.2004.07.008 Weiss, 2010, Probiotic Supplementation Affects Pulmonary Exacerbations in Patients with Cystic Fibrosis: A Pilot Study, Ped Pulmonol, 45, 536, 10.1002/ppul.21138 Zeitlin, 2017, Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics and Dose Finding, Ann Am Thorac Soc, 14, 220, 10.1513/AnnalsATS.201608-649OC Asner, 2012, Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis, J Cyst Fibros, 11, 433, 10.1016/j.jcf.2012.04.006 Hentschel, 2015, Protease-antiprotease imbalances differ between Cystic Fibrosis patients’ upper and lower airway secretions, J Cyst Fibros, 14, 324, 10.1016/j.jcf.2014.09.003 Moeller, 2010, Effects of a Short-Term rehabilitation Program on Airway Inflammation in Children with Cystic Fibrosis, Ped Pulmonol, 45, 541, 10.1002/ppul.21167 Niggeman, 1995, Myeloperoxidase and eosinophil cationic protein in serum and sputum during antibiotic treatment in cystic fibrosis patients with Pseudomonas aeruginosa infection, Med Inflamm, 4, 282, 10.1155/S0962935195000457 Worlitzsch, 1998, Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis, ERJ, 11, 377, 10.1183/09031936.98.11020377 Regelmann, 1995, Sputum Peroxidase Activity Correlates with the Severity of Lung Disease in Cystic Fibrosis, Ped Pulmonol, 19, 1, 10.1002/ppul.1950190102 Eckrich, 2017, Airway Inflammation in Mild Cystic Fibrosis, J Cyst Fibros, 16, 107, 10.1016/j.jcf.2016.05.016 Hansen, 2010, Inflammation in Achromobachter xylosoxidans infected cystic fibrosis patients, J Cyst Fibros, 9, 51, 10.1016/j.jcf.2009.10.005 Gray, 2010, Sputum and serum calprotectin are useful biomarkers during CF exacerbation, J Cyst Fibros, 9, 193, 10.1016/j.jcf.2010.01.005 Zemanick, 2013, Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations, PLoS ONE, 8, 10.1371/journal.pone.0062917